According to the latest analysis by Future Market Insights (FMI), the global pharmacovigilance market is on a trajectory of substantial growth, with projections indicating a remarkable increase from USD 6.87 billion in 2023 to USD 23.31 billion by 2033. This surge reflects a robust Compound Annual Growth Rate (CAGR) of 13% over the forecast period.
The growth of the pharmacovigilance market is driven by several key factors. There is a burgeoning emphasis on drug safety and regulatory compliance across the pharmaceutical industry, accompanied by heightened awareness within both the healthcare sector and the general public regarding the critical importance of effective adverse drug reaction monitoring.
Achieve Business Milestones with Informed Strategies: Access Request Checkout Now
Technological advancements in data processing and analysis are also pivotal in driving this market expansion. These innovations are significantly enhancing the efficiency and efficacy of pharmacovigilance activities, thereby enabling better management and monitoring of drug safety profiles.
Key Drivers Fueling the Growth:
- Rising Prevalence of Chronic Diseases: The increasing incidence of chronic illnesses like diabetes, cancer, and cardiovascular diseases necessitates the development of new pharmaceuticals. This, in turn, fuels the demand for robust pharmacovigilance practices to ensure patient safety.
- Growing Awareness of Adverse Drug Reactions (ADRs): Heightened awareness of ADRs, coupled with increasing patient consumption of medications, propels the need for enhanced pharmacovigilance services.
- Stringent Regulatory Frameworks: Stringent regulations mandating thorough drug safety monitoring by pharmaceutical companies and regulatory bodies further drive market expansion.
North America Leads the Charge:
- North America currently holds the largest market share (over 30.0% in 2021) due to the presence of major pharmaceutical and medical device players. Additionally, the rising problem of drug abuse and associated ADRs contributes significantly to market growth.
- The United States, a global leader in pharmaceuticals, holds a dominant position within North America, accounting for 30.9% of the global market share in 2022. This dominance is attributed to strict regulatory frameworks, patient safety emphasis, and a growing focus on patient-centric pharmacovigilance.
Europe and Asia Pacific: Emerging Markets with Promise:
- Europe presents potential for growth, with the UK leading the way due to an increased number of clinical trials evaluating new drug candidates.
- Germany, a leader in innovation and technology, embraces advanced pharmacovigilance tools like AI and big data to streamline adverse event reporting.
- The Asia Pacific region is expected to witness the fastest CAGR during the forecast period, driven by the abundance of outsourcing companies offering cost-effective and resource-sharing opportunities.
- China and India, experiencing rapid growth in their pharmaceutical industries, are key players in the Asia Pacific market. This growth necessitates stricter pharmacovigilance measures to ensure drug safety.
Instant Access to Strategic Insights – Get A Full Report Now
Competitive Landscape in the Pharmacovigilance Market:
In the pharmacovigilance industry, key players, including pharmaceutical companies, regulatory authorities, and specialized service providers, are actively monitoring and assessing the safety of drugs and medical products. They collaborate to detect, evaluate, and manage adverse effects, ensuring patient safety and compliance with regulations. Additionally, these players invest in advanced technologies and data analytics to enhance pharmacovigilance processes and stay at the forefront of drug safety management.
Recent Developments by Key Players:
Qinecsa Solutions Ltd. achieved a significant accomplishment in December 2022 by acquiring Commonwealth Informatics, Inc. This milestone has enabled Qinecsa to establish a comprehensive vigilance platform, bringing together outstanding pharmacovigilance services with a powerful digital platform.
In June 2022, the Italian Medicines Agency launched the new National Pharmacovigilance Network (RNF) along with an international standard format for gathering data on adverse reactions. The RNF serves as the system responsible for collecting, managing, and analyzing reports of suspected ADRs in Italy. The updated RNF incorporates advanced features to enhance the management and analysis of these reports.
Key Players:
- Accenture Plc.
- Bristol-Myers Squibb
- Clinquest Group B.V.
- Cognizant Technology Solutions
- Covance Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- ICON Plc
- iGATE Corporation
- iMED Global Corporation
- inVentiv Health Inc.
Key segments:
By Phase of Drug Development:
- Preclinical Studies
- Phase I
- Phase II
- Phase III
- Phase IV
By Type of Methods:
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
By Service Type Provider:
- In-house Pharmacovigilance
- Contract Outsourcing
By Geography:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube